Jamieson Wellness Inc. to Accelerate Growth with Strategic Acquisition in China

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX:JWEL) announced today that the Company has reached an agreement to acquire tangible and intangible assets from its distribution partner in China, allowing it to directly operate its sales, marketing and distribution activities in China effective April 1, 2023.

Under its previous distribution agreement, the Company's distribution partner maintained exclusive rights to distribute and market Jamieson Wellness-owned brands through cross border e-commerce, domestic retail and online channels in China. While the Company's historical operational approach has generated strong results in-market, this acquisition is a significant step forward in its brand expansion plans in China, allowing it to take a more direct and holistic approach to delivering brand experiences for Chinese consumers in this key international market.

"The Chinese market offers exciting growth opportunities for our business, and this acquisition marks the next step towards harnessing them," said Mike Pilato, President and CEO of Jamieson Wellness. "Our business in China continues to outpace the industry average, and with our previous distribution contract set to expire at the end of 2022, we felt it is time to align our direct go-to-market strategy with a clear focus on growing our business for the long-term.

"Moving forward, we will directly manage the customer and consumer relationships with our team in China. Powered by our strong brand and the ownership of our complete value chain we will accelerate momentum by increasing investment in traditional marketing, channel expansion, and direct consumer communication activities. Our goal to truly scale our China business is transformational, and in-line with the brand demand that Chinese consumers have shown for Jamieson and our 100-year history of quality and trust. This is a remarkable time at Jamieson Wellness, as we enter our next century of growth with these advancements in support of our mission to become the world's most successful and trusted health and wellness company."

China is the second-largest vitamin market in the world, experiencing growth outpacing the global industry average. The Company has a three-pronged strategy in the country, delivering growth in cross border e-commerce, domestic retail and e-commerce, and holding a category leadership position with its international club partners. In anticipation of this transition to a Company-owned distribution model, the Company is in the process of expanding its Shanghai office (Jamieson Health Products (Shanghai) Co., Ltd.) and team, which includes general management, sales, finance, marketing, procurement, regulatory and quality professionals. The Company continues to consider additional strategic partnerships to accelerate growth and strengthen its position in mainland China. Ownership of the assets will come into effect on April 1, 2023, subject to customary closing conditions, and the current distribution partner will work with the Company's team on the ground in China until July 1, 2023, to help ensure a smooth transition and continued momentum of the Jamieson brand while executing on the Company's growth aspirations.

About Jamieson Wellness Inc.

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's growth opportunities, its plans to increase investment and consider additional partnerships, and its plans to expand its offices and team in China.

Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 29, 2022 and under the "Risk Factors" section in the management's discussion and analysis of financial condition and results of operations of the Company filed today, November 3 rd , 2022 (the "MD&A"). This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact:
Ruth Winker
Jamieson Wellness
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks of 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.

Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-on-year gains. All data was compiled on July 18, 2025, using TradingView’s stock screener, and companies with market caps above C$10 million at that time were considered.

Keep reading...Show less
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less

Latest Press Releases

Related News

×